Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines current treatment strategies for trichotillomania, noting that while cognitive-behavioral therapy is effective, N-acetylcysteine and memantine are also recommended due to their safety and efficacy, though evidence for other drugs like fluoxetine and naltrexone remains limited.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This review discusses a new multidisciplinary guideline for treating male hypogonadism and emphasizes a comprehensive approach but reports no new experimental results.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

This review outlines the use of quantitative imaging techniques in monitoring tendon response to platelet-rich plasma treatment for chronic tendinopathy and reports that these methods may aid in tailoring PRP protocols.

This study found that VMAT hair-sparing WBRT partially preserved scalp hair at four weeks post-treatment without compromising symptomatic disease control in the short term, but reduced hair loss did not improve quality of life.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

In this study, the researchers developed and optimized a bilayer tablet containing Tamsulosin and Finasteride, achieving sustained and immediate drug release with favorable release kinetics, including first-order and anomalous diffusion mechanisms, through in vitro testing.

This article explores the historical development and evolution of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), emphasizing advancements in safety and technology, and reports no new clinical results.

Tigason improved hair growth in a boy with monilethrix without side effects.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This study found that mirex and TPA promote papilloma formation in CD-1 mouse skin through distinct populations of mutant Ha-ras cells, resulting in additive tumor yields.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

In this study, introducing the rat OTC gene into spf-ash mice led to increased OTC activity and normalized hair growth and biochemical markers like urinary orotic acid and serum citrulline, partially correcting the symptoms of OTC deficiency.

In this study, the authors found that targeting mTORC1 with rapamycin inhibited TPA-induced skin tumor promotion by affecting keratinocyte proliferation, including critical stem cell populations in the mouse epidermis.

This review discusses the mechanisms, uses, and side effects of conventional synthetic DMARDs, particularly methotrexate, for rheumatoid arthritis, but reports no new clinical findings.

This article reviews the author's experience and favored techniques for using Radiesse in cosmetic treatments but reports no new clinical trial results.